SCHOLAR ROCK HOLDING CORPORATION Weighted Average Number of Limited Partnership and General Partnership Unit Outstanding, Basic and Diluted
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Weighted Average Number of Limited Partnership and General Partnership Unit Outstanding, Basic and Diluted of 1.60 million shares for the 3-month period ending 2017-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfLimitedPartnershipAndGeneralPartnershipUnitOutstandingBasicAndDiluted · last filed 2018-11-08
- SCHOLAR ROCK HOLDING CORPORATION weighted average number of limited partnership and general partnership unit outstanding, basic and diluted for the quarter ending 2017-09-30 was 1.60M shares.
- SCHOLAR ROCK HOLDING CORPORATION weighted average number of limited partnership and general partnership unit outstanding, basic and diluted for the quarter ending 2017-06-30 was 1.60M shares.
| Period end | Weighted Average Number of Limited Partnership and General Partnership Unit Outstanding, Basic and Diluted 3 month | Weighted Average Number of Limited Partnership and General Partnership Unit Outstanding, Basic and Diluted 6 month | Weighted Average Number of Limited Partnership and General Partnership Unit Outstanding, Basic and Diluted 9 month |
|---|---|---|---|
| 2017-09-30 | 1.60M shares 10-Q · filed 2018-11-08 | 1.60M shares 10-Q · filed 2018-11-08 | |
| 2017-06-30 | 1.60M shares 10-Q · filed 2018-08-08 | 1.60M shares 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |